<DOC>
	<DOCNO>NCT01364883</DOCNO>
	<brief_summary>This open label phase I study , assess safety immunogenicity novel schedule vaccination candidate malaria vaccine AdCh63 ME-TRAP MVA ME-TRAP . These vaccine evaluate previously number clinical trial prove safe capable induce protective cellular immune response follow challenge parasite . All volunteer recruit healthy adult . They prim AdCh63 ME-TRAP administer intramuscularly boost several time AdCh63 ME-TRAP MVA ME-TRAP accord various schedules.. Safety data collect seven regimen . Secondary aim study assess immune response generate regime .</brief_summary>
	<brief_title>Safety Immunogenicity Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP MVA ME-TRAP</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult age 18 50 year Able willing ( Investigator 's opinion ) comply study requirement Willing allow investigator discuss medical history General Practitioner For female volunteer , willingness practice continuous effective contraception study Agreement refrain blood donation course study Written inform consent Participation another research study involve investigational product 30 day precede enrolment , plan use study period Prior receipt investigational malaria vaccine investigational vaccine likely impact interpretation trial data Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate Any confirm suspected immunosuppressive immunodeficient state , include HIV infection ; asplenia ; recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) Pregnancy , lactation , intention become pregnant study History allergic disease reaction likely exacerbate component vaccine , e.g . egg product , Kathon History clinically significant contact dermatitis Any history anaphylaxis relation vaccination Any history malaria Travel malaria endemic region study period within six month precede enrolment study History serious psychiatric condition may affect participation study Any serious chronic illness require hospital specialist supervision Suspected known current alcohol abuse define alcohol intake great 42 unit every week Suspected known inject drug abuse five year precede enrolment Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV ) Any relevant history cancer ( exclude basal cell carcinoma skin cervical carcinoma situ ) Any clinically significant abnormal find screen biochemistry haematology blood test urinalysis Any significant disease , disorder finding may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Immune response</keyword>
</DOC>